Lucid Diagnostics (LUCD) Announces Closing of Public Offering of Common Stock

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten public offering of 14,375,000 shares of its common stock, including 1,875,000 shares issued pursuant to the exercise of the underwriters' option to purchase additional shares, at a public offering price of $1.20 per share.

The total net proceeds from the offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $16.1 million. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

Canaccord Genuity LLC acted as the sole bookrunner of the offering, and Maxim Group LLC acted as co-manager.

You May Also Be Interested In

• Gordon Haskett cuts TJX Companies rating to Accumulate
• Qnity installs KLA wafer inspection system in Massachusetts fab
• Guggenheim Reiterates Neutral Rating on CrowdStrike (CRWD)